LAZZARIN, ADRIANO
 Distribuzione geografica
Continente #
EU - Europa 1.189
NA - Nord America 813
AS - Asia 450
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 4
OC - Oceania 1
Totale 2.468
Nazione #
US - Stati Uniti d'America 807
SE - Svezia 714
SG - Singapore 225
RU - Federazione Russa 190
CN - Cina 186
IT - Italia 177
FI - Finlandia 49
IN - India 27
DE - Germania 21
IE - Irlanda 17
CA - Canada 6
EU - Europa 5
BR - Brasile 4
GB - Regno Unito 4
CZ - Repubblica Ceca 3
HK - Hong Kong 3
IR - Iran 3
MD - Moldavia 3
NL - Olanda 3
BE - Belgio 2
FR - Francia 2
JP - Giappone 2
TH - Thailandia 2
TN - Tunisia 2
UA - Ucraina 2
ZA - Sudafrica 2
AR - Argentina 1
AU - Australia 1
EC - Ecuador 1
ES - Italia 1
KW - Kuwait 1
RS - Serbia 1
TR - Turchia 1
Totale 2.468
Città #
Lawrence 219
Princeton 219
Singapore 131
Moscow 102
Milan 96
Ashburn 77
New York 74
Shanghai 68
Helsinki 47
Boardman 38
Pune 22
Dublin 14
Guangzhou 10
Seattle 8
Rome 7
Washington 7
Dallas 6
Shenzhen 5
Beijing 4
Borås 4
Hamilton 4
Los Angeles 4
Ortezzano 4
West Jordan 4
Angera 3
Ballincollig 3
Chisinau 3
Curitiba 3
Padova 3
Quanzhou 3
Santa Clara 3
Duchcov 2
Durban 2
Florence 2
Ghent 2
Hanover 2
Hyderabad 2
Lappeenranta 2
Nuremberg 2
Panchkula 2
Povegliano 2
Redwood City 2
Segrate 2
St Petersburg 2
Taizhou 2
Tehran 2
Tokyo 2
Torre Del Greco 2
Tualatin 2
Turin 2
Vittoria 2
Wanchai 2
Wuxi 2
Bangkok 1
Belgrade 1
Buffalo 1
Campodolcino 1
Castelletto sopra Ticino 1
Castiglion Fiorentino 1
Dalmine 1
Dongyang 1
Falkenstein 1
Gatchina 1
Giussano 1
Haining 1
Haywards Heath 1
Henderson 1
Isfahan 1
Kuwait City 1
Lainate 1
London 1
Louth 1
Madignano 1
Madrid 1
Mountain View 1
Paliano 1
Parma 1
Pavia 1
Perm 1
Perugia 1
Pisa 1
Quito 1
Reading 1
Reston 1
San Sperate 1
Secaucus 1
Seravezza 1
Sertãozinho 1
Shaoxing 1
Sydney 1
Taranto 1
Tianjin 1
Tradate 1
Truccazzano 1
Vancouver 1
Viedma 1
West Hartford 1
West Valley City 1
Xi'an 1
Totale 1.285
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 46
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 43
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 36
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 31
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 31
Biobanking for COVID-19 research 29
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 26
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 25
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 23
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 23
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 22
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 22
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 21
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 21
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 21
Early diagnosis of HIV infection in infants 20
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 20
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 20
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 20
ABC of AIDS: Treatment of infections and antiviral agents 20
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 19
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 19
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 19
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 19
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 19
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 18
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 18
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 18
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 18
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 17
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 17
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 17
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 16
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 16
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy 16
Bictegravir 16
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 16
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 16
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 16
GB Virus C and Survival in Persons with HIV Infection 15
Immunological status in heroin addicts: effects of methadone maintenance treatment 15
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 15
Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients 15
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 15
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 15
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 15
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 15
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 15
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 15
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 15
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 15
Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study 15
HEFFICON: HIV Effectiveness Italian Conference 15
Dynamics of the M184V mutation by allele-specific PCR (AS-PCR) in patients receiving lamivudine or emtricitabine monotherapy or undergoing treatment interruption (TI) 15
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 14
Experiences with immunomodulant agents in HIV infections 14
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 14
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 14
Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors 14
Diagnosis of toxoplasmic encephalitis in HIV-infected patients 14
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 14
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 14
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 14
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 14
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 14
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 14
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 14
Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine 14
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 14
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 13
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy 13
Impairment of in vitro natural antibacterial activity in HIV-infected patients 13
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 13
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients 13
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts 13
Increased hyperglycaemia during cotreatment with pentamidine and corticosteroids in AIDS patients 13
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 13
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 13
Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography 13
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015 13
Risk of HIV infection in recipients of blood and blood products 13
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 13
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 13
FAILURE TO DARUNAVIR/RITONAVIR CAN EITHER INCREASE OR DECREASE TIPRANAVIR/RITONAVIR GENOTYPIC RESISTANCE SCORE IN HIGHLY TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS 13
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 13
Durability of a novel salvage therapy in R5 HIV-infected patients: maraviroc, raltegravir, etravirine 13
Carotid vessels lesions in experienced HIV-1-infected subjects affected or not by hypertension and/or diabetes mellitus 13
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 12
Impact of HAART on liver histology of HIV/HCV coinfected patients 12
Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women 12
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection 12
Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients 12
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin 12
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016 12
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism 12
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 12
REAL-LIFE EXPERIENCE OF DAA-BASED REGIMENS PLUS RIBAVIRIN IN CIRRHOTIC PATIENTS COINFECTED WITH HCV AND HIV-1 12
Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients 12
Rugarli. Medicina interna sistematica 12
Reply 12
Totale 1.675
Categoria #
all - tutte 49.444
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.444


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 1 0 0 0 0 0 0 1
2020/202191 0 0 1 6 0 14 11 57 1 0 1 0
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/2025473 375 58 37 3 0 0 0 0 0 0 0 0
Totale 2.721